About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global Expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information ESG Contact us
Products Services
Product center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Career
Talent R&D Team Employee Life Job Opportunities
EN
CN
About Us
· Company Introduction · Strategic Development · Social Responsibility
Scientific Research
· Innovative Layout · Innovative Field
Products Services
· Product center · Product branding · Quality & Safety
News
· Company News · Media Coverage · Media Inquiries · Multimedia zone
Vocational
· Concept about Talent · R&D Team · Employee Life · Job Opportunities
> News > Company
Return
Employer Presentations at Wuhan University and Huazhong University of Science and Technology
2024-04-24

Grand Pharma has built a bridge between our company and the universities in Wuhan. Recently, Grand Pharma conducted two employer presentations at Wuhan University and Huazhong University of Science and Technology. Our colleagues responsible for pharmaceutical R&D had pleasant talks with the students from their own professional experience. After the event, our team had a full harvest of interviews with these talents.

Prev

Next

Related news

  • The Global Innovative Product 莱特灵®/Ryaltris® (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray) Is Approved for Commercialization in China
    The Global Innovative Product 莱特灵®/Ryaltris® (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray) Is Approved for Commercialization in China

    2026-03-24

  • The Global Innovative Product TP-03 for the Treatment of Demodex Blepharitis Is Approved for Commercialization in China
    The Global Innovative Product TP-03 for the Treatment of Demodex Blepharitis Is Approved for Commercialization in China

    2026-03-23

  • The NDA of Grand Pharma’s Global Innovative RDC TLX591-CDx Is Accepted by the NMPA
    The NDA of Grand Pharma’s Global Innovative RDC TLX591-CDx Is Accepted by the NMPA

    2026-01-20

Grand Pharma Group
About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information Contact us
Products Services
Product Center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Vocational
Concept about Talent R&D Team Employee Life Job Opportunities
Copyright © Grand Pharma (China) Co., Ltd. All Rights Reserved E ICP B 10008288 EGWAB 42010402000597
Legal Provisions